Deng Mario C
Department of Medicine, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, Milstein Hospital Building, New York, NY 10032, USA.
Surg Clin North Am. 2004 Feb;84(1):243-55. doi: 10.1016/S0039-6109(03)00212-3.
A little more than three decades after the successful introduction of cardiac transplantation, this revolutionary concept of advanced heart failure treatment has gained tremendous momentum and is considered the gold standard therapy in selected patients. More specific modalities of immunosuppression continue to decrease the impact of acute and chronic rejection and immunosuppression-related side effects. The success of cardiac transplantation has led to a widespread initiation of transplant programs and a run on cardiac transplantation waiting lists. The increasing gap between waiting lists and donor organ supply has stimulated research to identify those patients who benefit most from cardiac transplantation, as well as research to develop alternative therapies for advanced heart failure. Furthermore, it serves as a stimulus to address paradigmatic issues that are fundamental to modern medicine and society.
在心脏移植成功引入三十多年后，这种先进的心力衰竭治疗的革命性概念已获得巨大发展势头，并被视为特定患者的金标准疗法。更具针对性的免疫抑制方式持续降低急性和慢性排斥反应以及免疫抑制相关副作用的影响。心脏移植的成功导致移植项目广泛启动，心脏移植等候名单供不应求。等候名单与供体器官供应之间日益扩大的差距促使人们开展研究，以确定那些从心脏移植中获益最大的患者，同时也推动了针对晚期心力衰竭的替代疗法的研究。此外，它还促使人们去解决现代医学和社会的一些根本性范式问题。
